查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2017014

病毒載體與質體DNA生產市場：2026-2032年全球市場預測（依產品類型、服務類型、工作流程階段、生產平台、生物製程方法、原料、應用、最終用戶和疾病領域分類）

Viral Vector & Plasmid DNA Manufacturing Market by Product Type, Service Type, Workflow Stage, Production Platform, Bioprocess Mode, Source, Application, End User, Disease Area - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，病毒載體和質體DNA 生產市場價值將達到 52.4 億美元，到 2026 年將成長到 61 億美元，到 2032 年將達到 156.7 億美元，年複合成長率為 16.91%。

主要市場統計數據
基準年 2025 52.4億美元
預計年份：2026年 61億美元
預測年份 2032 156.7億美元
複合年成長率 (%) 16.91%

策略概述，闡述製造穩健性、監管合規性和平台選擇如何決定先進生物製藥的臨床和商業性成功。

病毒載體和質體DNA的研發和生產如今已成為許多治療方法的基石，涵蓋基因療法、細胞療法、溶瘤病毒療法以及先進疫苗等領域。該產業正從概念驗證（PoC）階段邁向規模化生產階段，而規模化生產則強調可重複性、合規性和供應鏈韌性。因此，投資者、研發人員和製造商必須將製程開發、分析嚴謹性和可製造性視為專案成功的策略性決定因素，而不僅僅是後續的障礙。

對正在重新定義先進基因治療方法製造環境的模式轉移技術、監管和營運趨勢進行詳細檢驗。

近年來，病毒載體和質體DNA的設計、開發和生產方式發生了翻天覆地的變化。技術平台已從分散的實驗室規模製程發展為更模組化和擴充性的系統，從而實現了從實驗室到臨床的快速轉化。一次性技術、先進的生物反應器設計以及轉染效率和病毒產量的提高，促進了製程整合，並提高了批次間的一致性。同時，分析能力也得到了發展，能夠進行更詳細的分子和功能表徵，從而建立了更嚴格的放行標準，並提高了批次間的可比性。

對 2025 年新關稅政策將如何重塑生技藥品製造專案的採購、資本規劃和供應鏈韌性進行策略分析。

2025年實施的政策措施為全球生物製藥供應鏈帶來了新的顛覆性因素。關稅正在影響病毒載體和質體DNA生產所必需的試劑、耗材和專用設備。這些關稅的累積效應正蔓延至籌資策略、資本計畫和合作夥伴選擇，迫使各企業重新評估其採購模式和合約結構。對許多公司而言，最直接的影響在於重新評估供應商風險狀況，並在近岸外包和多元化採購之間進行權衡，以保障專案進度和利潤率。

為了進行策略性澄清，洞察基於全面的細分，將產品類型、服務、工作流程階段、平台、流程模式、採購、應用、使用者和疾病目標連結起來。

要了解市場動態，需要從產品類型、服務產品、工作流程階段、平台、製程模式、籌資策略、應用、最終用戶和治療領域等多個觀點進行細緻入微的分析。從產品類型角度來看，質體DNA和病毒載體之間的差異至關重要。病毒載體本身包括腺結合病毒載體、腺病毒載體、單純皰疹病毒載體、慢病毒載體和逆轉錄病毒載體，每種載體都有其獨特的工藝和監管考量，這些都會影響生產決策。服務組合反映了行業在其整個生命週期中的需求。分析測試、生產製造、製程開發、法規事務和CMC（化學、生產和品管）支援都發揮互補作用。製程開發涵蓋下游最佳化、製劑開發、放大生產和技術轉移，以及上游最佳化，旨在連接藥物發現的早期階段和可靠的商業化生產。

區域戰略展望，詳細闡述美洲、歐洲、中東和非洲以及亞太地區不同的管理體制、人才庫和生產能力趨勢如何影響製造業戰略。

區域趨勢正顯著影響著整個病毒載體和質體DNA生態系統的能力建構、監管互動和商業策略。在美洲，大量活躍的合資企業和臨床項目推動了對合約研發生產機構（CDMO）產能和先進分析技術的需求，而監管機構則繼續優先考慮早期對話和明確的CMC要求。該地區擁有豐富的生物程序工程和轉化科學人才儲備，但也面臨著熟練勞動力短缺的競爭以及為支持工藝進步而需要進行基礎設施現代化改造的困境。

提供實用的商業策略見解，揭示如何利用專業化、夥伴關係和營運柔軟性來確保製造優勢。

病毒載體和質體DNA領域的主要企業正採取一系列策略性措施以確保競爭優勢，包括平台專業化、有針對性地擴大產能以及選擇性垂直整合。一些企業專注於在特定載體類別和製程步驟方面累積深厚的專業知識，開發專有的製程技術和分析工具包，以縮短臨床試驗時間。另一些企業則優先考慮柔軟性，投資建造模組化設施和多產品線，以支援多樣化的專案並減少轉換時間。

為確保生產連續性，提出了優先考慮的、可操作的建議，包括技術投資、供應鏈韌性、監管合作和人力資源發展。

產業領導者應採取一系列切實有效的措施來應對技術複雜性、政策不確定性和競爭壓力。首先，優先投資於能夠實現模組化和多產品製造的平台，從而在專案流程變更時保持靈活性。其次，在關鍵試劑和儀器的供應商關係多元化的同時，開發檢驗的輔助訊息，以降低單點故障 (SPOF) 的風險。第三，將先進的分析和數位化品管系統整合到開發和製造的各個階段，以加速對製程的理解並支持監管申報。

採用透明且合理的混合方法研究途徑，結合專家訪談、文獻整合、檢驗和情境分析，為可靠的決策支援提供基礎。

本分析的調查方法融合了第一手資料和第二手資料，以確保研究結果的穩健性、多方驗證性和可操作性。第一手資料包括對製程開發、生產營運、品質保證和法規事務等領域的專家進行結構化訪談。透過這些訪談，我們從贊助商、服務供應商和研究機構的觀點獲得了關於瓶頸、產能缺口和策略重點的定性見解。第二手資料則整合了同行評審文獻、監管指南、技術白皮書和公開訊息，以闡明技術趨勢和政策發展的背景。

為了推進高度可靠的項目，需要簡潔地整合策略挑戰，強調科學創新、製造嚴謹性和監管合規性的整合。

這項分析強調，對於開發病毒載體和質體DNA療法的企業而言，卓越的生產製造如今已成為一項策略挑戰。製程選擇、平台策略和監管準備是密切相關的因素，它們決定一個專案能否高效地推進臨床開發並最終實現商業化供應。除了技術成熟度之外，營運創新以及對分析能力和人才培養的針對性投資，也能幫助企業降低生產變異性並縮短臨床試驗週期。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：病毒載體與質體DNA生產市場：依產品類型分類

  • 質體DNA
  • 病毒載體
    • 腺結合病毒載體
    • 腺病毒載體
    • 單純皰疹病毒（HSV）載體
    • 慢病毒載體
    • 逆轉錄病毒載體

第9章：病毒載體與質體DNA生產市場：依服務類型分類

  • 分析測試
  • 製造業
  • 製程開發
    • 下游最佳化
    • 配方開發
    • 規模擴大/技術轉移
    • 上游工程最佳化
  • 法規遵從性和CMC支持

第10章：病毒載體與質體DNA生產市場：依工作流程階段分類

  • 下游工藝
    • 捕獲
    • 宣言
    • 濃度/緩衝交換
    • 中間純化
    • 拋光
  • 填充和精加工
  • 發布和穩定性測試
  • 上游工程
    • 生物反應器生產
    • 細胞增殖
    • 轉染/轉導

第11章：病毒載體與質體DNA生產市場：依生產平台分類

  • 細菌
  • 無細胞系統
  • 昆蟲
  • 哺乳動物
  • 酵母菌

第12章：病毒載體與質體DNA生產市場：依生物製程方法分類

  • 批次
  • 文化形式
    • 黏附培養
    • 懸浮培養
  • 聯邦批次
  • 灌注

第13章：病毒載體與質體DNA生產市場：依原料分類

  • 內部生產
  • 外包/CDMO

第14章：病毒載體與質體DNA生產市場：依應用領域分類

  • 細胞療法
  • 基因編輯
  • 基因治療
  • 溶瘤病毒療法
  • 研究與開發
  • 疫苗研發

第15章：病毒載體與質體DNA生產市場：依最終用戶分類

  • 生物製藥公司
  • 合約研發生產組織（CDMO）
  • 合約研究組織（CRO）
  • 研究機構

第16章：病毒載體與質體DNA生產市場：依疾病領域分類

  • 循環系統
  • 肝病
  • 感染疾病
  • 代謝/內分泌
  • 肌肉骨骼系統
  • 神經病學
  • 腫瘤學
  • 眼科
  • 罕見遺傳疾病

第17章：病毒載體與質體DNA生產市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第18章：病毒載體與質體DNA生產市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第19章：病毒載體與質體DNA生產市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第20章：美國：病毒載體與質體DNA生產市場

第21章 中國：病毒載體與質體DNA生產市場

第22章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Advanced BioScience Laboratories, Inc.
  • Akron Biotech
  • Aldevron, LLC
  • Avid Bioservices, Inc.
  • Batavia Biosciences BV
  • BioNTech IMFS GmbH
  • BioSpace, Inc.
  • Biovian Oy
  • c-LEcta GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Creative Biogene
  • Cytiva by Danaher Corporation
  • FILTROX AG
  • Forge Biologics By Ajinomoto Co., Inc.
  • FUJIFILM Diosynth Biotechnologies Inc.
  • GE HealthCare Technologies, Inc.
  • Genentech, Inc.
  • GeneOne Life Science, Inc.
  • Genezen Laboratories, Inc.
  • GenScript Biotech Corporation
  • Hillgene Biopharma Co., Ltd.
  • Kaneka Eurogentec SA
  • Lonza Group Ltd.
  • Merck KGaA
  • Miltenyi Biotec BV & Co. KG
  • Oxford Biomedica plc
  • POLYPLUS TRANSFECTION SA
  • REGENXBIO Inc.
  • Revvity, Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Twist Bioscience Corporation
  • uniQure NV
  • Wuxi AppTec Co., Ltd.
Product Code: MRR-030298DFFC33

The Viral Vector & Plasmid DNA Manufacturing Market was valued at USD 5.24 billion in 2025 and is projected to grow to USD 6.10 billion in 2026, with a CAGR of 16.91%, reaching USD 15.67 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.24 billion
Estimated Year [2026] USD 6.10 billion
Forecast Year [2032] USD 15.67 billion
CAGR (%) 16.91%

A strategic introduction describing how manufacturing robustness, regulatory alignment, and platform selection determine clinical and commercial success in advanced biologics

The development and manufacture of viral vectors and plasmid DNA now underpin a rapidly expanding set of therapeutic modalities, from gene therapies and cell therapies to oncolytic virotherapies and advanced vaccines. The industry is moving beyond proof-of-concept activity and toward production-scale realities, with an emphasis on reproducibility, regulatory compliance, and supply chain resilience. Investors, developers, and manufacturers must therefore view process development, analytical rigor, and manufacturability as strategic determinants of program success rather than downstream obstacles.

Recent technological progress has reduced some historical barriers to entry, yet it has also introduced new complexities. Advances in vector design and plasmid construct engineering have amplified demands on upstream and downstream processing, while heightened regulatory expectations have elevated the importance of quality systems and CMC documentation. Consequently, leaders must navigate a landscape where scientific innovation, manufacturing capability, and regulatory strategy converge to determine clinical and commercial viability.

Transitioning from laboratory-scale production to consistent clinical and commercial supply requires deliberate planning across platform selection, workforce competencies, and vendor ecosystems. As programs advance to later-stage clinical development, manufacturers must align process robustness with regulatory engagement, while anticipating capacity constraints and capital needs. This introduction sets the stage for a deeper examination of structural shifts, policy impacts, segmentation nuance, and actionable recommendations for organizations operating within this dynamic field.

An in-depth examination of paradigm-shifting technological, regulatory, and operational trends that are redefining the manufacturing landscape for advanced gene modalities

The last several years have seen transformative shifts that are reshaping how viral vectors and plasmid DNA are conceived, developed, and produced. Technology platforms have matured from fragmented, lab-scale processes into more modular, scalable systems, enabling faster translation from bench to clinic. Single-use technologies, advanced bioreactor designs, and improvements in transfection efficiency or viral production have driven process intensification and greater batch consistency. At the same time, analytical capabilities have evolved to provide deeper molecular and functional characterization, thereby enabling tighter release criteria and improved lot-to-lot comparability.

Concurrently, regulatory frameworks and industry expectations have moved toward greater harmonization and early engagement. Regulators increasingly emphasize control strategies, comparability demonstrations, and the use of orthogonal analytical methods to support product quality. In parallel, the growth of outsourced manufacturing and CDMO specialization is shifting strategic investment decisions: sponsors must balance in-house capabilities with the agility and scale offered by external partners. This dynamic environment is also seeing digitalization of manufacturing operations and adoption of data-driven quality systems, which together improve process control and facilitate regulatory submissions.

As a result, organizations that invest in adaptable platforms, robust analytics, and collaborative regulatory strategies are better positioned to capture the opportunities created by novel therapeutic modalities. The convergence of technological, regulatory, and commercial forces is creating an era in which manufacturing strategy is integral to therapeutic differentiation rather than a mere operational consideration.

A strategic analysis of how new tariff policies in 2025 are reshaping procurement, capital planning, and supply chain resilience for biologics manufacturing programs

Policy measures implemented in 2025 introduced a new variable into global supply chains for biologics manufacturing, with tariffs affecting reagents, consumables, and specialized equipment that are critical to viral vector and plasmid DNA production. The cumulative impact of these tariffs has rippled through procurement strategies, capital planning, and partner selection, prompting organizations to reassess sourcing models and contract structures. For many, the immediate effect has been a recalibration of supplier risk profiles and an examination of nearshoring versus diversification to protect program timelines and margins.

Beyond procurement, tariffs have influenced investment decisions around facility build-outs and equipment acquisition. Longer lead times and increased costs for certain imported components have caused some sponsors and CDMOs to reprioritize modular, flexible assets that accommodate multiple product types. In addition, contractual dynamics have shifted as buyers negotiate longer-term agreements or volume commitments to secure supply and mitigate price volatility. Fiscal unpredictability has underscored the importance of scenario planning and stress-testing supply chains against policy shocks.

To adapt, forward-looking organizations are developing mitigation strategies that include multi-sourcing critical reagents, increasing local inventory buffers for high-risk components, and collaborating more closely with suppliers to co-develop contingency plans. Engaging proactively with regulators and trade authorities also helps clarify compliance pathways for alternative materials. Ultimately, success in this environment requires a disciplined approach to procurement strategy, capital allocation, and cross-functional coordination to maintain program momentum in the face of evolving trade policy.

Comprehensive segmentation-driven insights connecting product types, services, workflow stages, platforms, process modes, sourcing, applications, users, and disease targets for strategic clarity

Understanding market dynamics requires a granular view across product types, service offerings, workflow stages, platforms, process modes, sourcing strategies, applications, end users, and therapeutic areas. From a product type perspective, distinctions between plasmid DNA and viral vectors are foundational; viral vectors themselves encompass adeno-associated viral vectors, adenoviral vectors, herpes simplex virus vectors, lentiviral vectors, and retroviral vectors, each with distinct process and regulatory considerations that shape manufacturing decision-making. Service portfolios reflect the industry's lifecycle needs: analytical testing, manufacturing, process development, and regulatory and CMC support all play complementary roles, with process development spanning downstream optimization, formulation development, scale-up and technology transfer, and upstream optimization to bridge early discovery and reliable commercial production.

The workflow stage segmentation-encompassing downstream processing, fill and finish, release and stability testing, and upstream processing-reveals opportunities and constraints that vary across process steps. Downstream activities such as capture, clarification, concentration and buffer exchange, intermediate purification, and polishing are technically demanding and often bottleneck-prone, while upstream activities like bioreactor production, cell expansion, and transfection or transduction determine yield and product quality early in the chain. Production platform choice-whether bacterial, cell-free systems, insect, mammalian, or yeast-further informs equipment selection, contamination control, and regulatory strategy.

Bioprocess mode choices including batch, culture format, fed-batch, and perfusion, with culture formats split into adherent and suspension systems, influence scale-up complexity and cost structure. Meanwhile, decisions around source-whether in-house manufacturing or outsourced CDMO partnerships-shape capital intensity and operational flexibility. Application areas from cell therapy, gene editing, gene therapy, oncolytic virotherapy, research and development, to vaccine development impose divergent quality, throughput, and timeline expectations. End users such as biopharmaceutical companies, CDMOs, CROs, and research institutions each require tailored service models, and disease area focus-spanning cardiovascular, hepatic, infectious, metabolic or endocrine, musculoskeletal, neurology, oncology, ophthalmology, and rare genetic disorders-affects regulatory pathways and commercial strategies. Synthesizing these segments reveals that technical choices and commercial models must be aligned with therapeutic goals to optimize development timelines and long-term sustainability.

Regional strategic perspectives detailing how distinct regulatory regimes, talent pools, and capacity dynamics across the Americas, EMEA, and Asia-Pacific influence manufacturing strategy

Regional dynamics exert a major influence on capability development, regulatory engagement, and commercial strategy across the viral vector and plasmid DNA ecosystem. In the Americas, robust venture activity and a dense concentration of clinical programs drive strong demand for CDMO capacity and advanced analytics, while regulatory agencies continue to emphasize early dialogue and clear CMC expectations. The region benefits from deep talent pools in bioprocess engineering and translational science, yet it also faces competition for skilled labor and the need to modernize infrastructure to support process intensification.

Europe, Middle East & Africa presents a heterogeneous landscape where established manufacturing hubs coexist with emerging centers of excellence. Regulatory regimes across the region vary, creating both opportunities for local innovation and challenges for cross-border program harmonization. Many organizations are developing regional strategies that leverage Europe's strong regulatory science base and specialized manufacturing expertise, while simultaneously managing logistics and compliance complexities that arise from multi-jurisdictional operations.

Asia-Pacific is characterized by rapidly expanding capacity, significant government support for biomanufacturing, and a growing number of specialized service providers. The region's manufacturing ecosystems are evolving quickly, with investments in both large-scale facilities and niche capabilities. As a result, Asia-Pacific is increasingly integrated into global supply chains, offering attractive options for cost-effective manufacturing, though companies must navigate differing regulatory expectations and quality assurance practices. Across all regions, successful players adapt their strategies to local strengths while maintaining global standards of quality and regulatory compliance.

Actionable corporate strategy insights revealing how specialization, partnerships, and operational flexibility are being deployed to secure manufacturing advantage

Leading organizations in the viral vector and plasmid DNA space are pursuing a range of strategic moves to secure competitive advantage, including platform specialization, targeted capacity expansion, and selective vertical integration. Some players focus on building deep expertise around particular vector classes or process steps, developing proprietary process know-how and analytical toolkits that reduce time to clinic. Others prioritize flexibility, investing in modular facilities and multi-product lines that support diverse programs and reduce changeover timelines.

Strategic partnerships and alliances are common, as sponsors collaborate with service providers to access capacity, regulatory expertise, and specialized technologies without committing to full-scale capital investments. Mergers and acquisitions have also emerged as a mechanism to accelerate capability acquisition and geographic expansion, particularly when time-to-market is critical. In parallel, investment in digital process control, quality systems modernization, and advanced analytics is helping organizations reduce variability and improve decision-making.

Collectively, these trends suggest that successful companies balance deep technical differentiation with operational elasticity. They combine scientific leadership in vector design or plasmid engineering with disciplined manufacturing and quality practices to support consistent supply. Firms that cultivate strong supplier relationships, invest in workforce development, and align commercial strategy with manufacturing capability are better positioned to support complex clinical programs and scale reliably into commercial markets.

A pragmatic set of prioritised recommendations for technology investment, supply chain resilience, regulatory engagement, and workforce development to secure manufacturing continuity

Industry leaders should adopt a set of practical, high-impact measures to navigate technological complexity, policy uncertainty, and competitive pressures. First, prioritize platform investments that enable modularity and multiproduct runs, thereby preserving agility when program pipelines shift. Second, diversify supplier relationships for critical reagents and equipment while developing verified secondary sources to reduce single-point-of-failure risks. Third, embed advanced analytics and digital quality systems across development and manufacturing to accelerate process understanding and support regulatory submissions.

Additionally, organizations should strengthen regulatory engagement by initiating early scientific advice and by validating orthogonal analytical methods that provide robust evidence of product quality. Strategic use of outsourcing for non-core functions can accelerate timelines, but it must be governed by rigorous vendor qualification and joint governance frameworks to ensure alignment on timelines and quality standards. Workforce development is equally essential; invest in targeted training that spans process development, quality, and data analytics to close skill gaps.

Finally, incorporate scenario planning into strategic reviews to stress-test programs against policy changes, supply disruptions, and shifts in demand. By combining operational resilience with focused technological investment and proactive regulatory dialogue, leaders can reduce program risk and create a foundation for sustainable growth in a rapidly evolving sector.

A transparent and defensible mixed-methods research approach combining expert interviews, literature synthesis, validation, and scenario analysis for reliable decision support

The research methodology underpinning this analysis integrates both primary and secondary approaches to ensure robustness, triangulation, and practical relevance. Primary research included structured interviews with subject-matter experts across process development, manufacturing operations, quality assurance, and regulatory affairs. These engagements provided qualitative insights into bottlenecks, capability gaps, and strategic priorities from the perspectives of sponsors, service providers, and research institutions. Secondary research synthesized peer-reviewed literature, regulatory guidance, technical white papers, and publicly available disclosures to contextualize technological trends and policy developments.

Data validation relied on cross-referencing interview findings with published process methods and regulatory precedents to confirm consistency and identify areas of divergence. Scenario analysis was used to examine the implications of policy shifts-such as tariff changes-and to model how different sourcing and capital strategies could affect program risk. The research also incorporated a review of advanced analytics and process control technologies to assess readiness for scale-up and regulatory submission.

Limitations include variability in proprietary process details and the evolving regulatory environment, which may alter guidance over time. To mitigate this, the methodology emphasizes transparency in assumptions and recommends periodic updates to reflect technological advancements and policy changes. The combined approach provides a defensible foundation for decision-making while remaining adaptable to new information.

A concise synthesis of strategic imperatives emphasizing the integration of scientific innovation, manufacturing rigor, and regulatory alignment to enable reliable program advancement

This analysis highlights that manufacturing excellence is now a strategic imperative for organizations developing viral vector and plasmid DNA therapeutics. Process selection, platform strategy, and regulatory preparedness are intertwined factors that determine whether programs can move efficiently through clinical development and into commercial supply. Technological maturation, coupled with operational innovation and targeted investments in analytics and workforce development, enables organizations to reduce variability and accelerate time to clinic.

Equally important is the need for adaptive supply chain strategies and proactive regulatory dialogue to manage external shocks such as policy changes or component shortages. Organizations that combine flexible manufacturing approaches with robust quality systems and strategic partnerships are better positioned to sustain program momentum and respond to evolving market demands. In conclusion, success in this domain will favor those who integrate scientific excellence with manufacturing pragmatism, embrace collaborative sourcing and regulatory strategies, and commit to continuous improvement of both processes and people.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Viral Vector & Plasmid DNA Manufacturing Market, by Product Type

  • 8.1. Plasmid DNA
  • 8.2. Viral Vector
    • 8.2.1. Adeno-Associated Viral Vectors
    • 8.2.2. Adenoviral Vectors
    • 8.2.3. Herpes Simplex Virus (HSV) Vectors
    • 8.2.4. Lentiviral Vectors
    • 8.2.5. Retroviral Vectors

9. Viral Vector & Plasmid DNA Manufacturing Market, by Service Type

  • 9.1. Analytical Testing
  • 9.2. Manufacturing
  • 9.3. Process Development
    • 9.3.1. Downstream Optimization
    • 9.3.2. Formulation Development
    • 9.3.3. Scale-Up/Technology Transfer
    • 9.3.4. Upstream Optimization
  • 9.4. Regulatory & CMC Support

10. Viral Vector & Plasmid DNA Manufacturing Market, by Workflow Stage

  • 10.1. Downstream Processing
    • 10.1.1. Capture
    • 10.1.2. Clarification
    • 10.1.3. Concentration/Buffer Exchange
    • 10.1.4. Intermediate Purification
    • 10.1.5. Polishing
  • 10.2. Fill & Finish
  • 10.3. Release & Stability Testing
  • 10.4. Upstream Processing
    • 10.4.1. Bioreactor Production
    • 10.4.2. Cell Expansion
    • 10.4.3. Transfection/Transduction

11. Viral Vector & Plasmid DNA Manufacturing Market, by Production Platform

  • 11.1. Bacterial
  • 11.2. Cell-Free Systems
  • 11.3. Insect
  • 11.4. Mammalian
  • 11.5. Yeast

12. Viral Vector & Plasmid DNA Manufacturing Market, by Bioprocess Mode

  • 12.1. Batch
  • 12.2. Culture Format
    • 12.2.1. Adherent
    • 12.2.2. Suspension
  • 12.3. Fed-Batch
  • 12.4. Perfusion

13. Viral Vector & Plasmid DNA Manufacturing Market, by Source

  • 13.1. In-House Manufacturing
  • 13.2. Outsourced/CDMO

14. Viral Vector & Plasmid DNA Manufacturing Market, by Application

  • 14.1. Cell Therapy
  • 14.2. Gene Editing
  • 14.3. Gene Therapy
  • 14.4. Oncolytic Virotherapy
  • 14.5. Research & Developement
  • 14.6. Vaccine Development

15. Viral Vector & Plasmid DNA Manufacturing Market, by End User

  • 15.1. Biopharmaceutical Companies
  • 15.2. Contract Development & Manufacturing Organizations (CDMOs)
  • 15.3. Contract Research Organizations (CROs)
  • 15.4. Research Institutions

16. Viral Vector & Plasmid DNA Manufacturing Market, by Disease Area

  • 16.1. Cardiovascular
  • 16.2. Hepatic Diseases
  • 16.3. Infectious Diseases
  • 16.4. Metabolic/Endocrine
  • 16.5. Musculoskeletal
  • 16.6. Neurology
  • 16.7. Oncology
  • 16.8. Ophthalmology
  • 16.9. Rare Genetic Disorders

17. Viral Vector & Plasmid DNA Manufacturing Market, by Region

  • 17.1. Americas
    • 17.1.1. North America
    • 17.1.2. Latin America
  • 17.2. Europe, Middle East & Africa
    • 17.2.1. Europe
    • 17.2.2. Middle East
    • 17.2.3. Africa
  • 17.3. Asia-Pacific

18. Viral Vector & Plasmid DNA Manufacturing Market, by Group

  • 18.1. ASEAN
  • 18.2. GCC
  • 18.3. European Union
  • 18.4. BRICS
  • 18.5. G7
  • 18.6. NATO

19. Viral Vector & Plasmid DNA Manufacturing Market, by Country

  • 19.1. United States
  • 19.2. Canada
  • 19.3. Mexico
  • 19.4. Brazil
  • 19.5. United Kingdom
  • 19.6. Germany
  • 19.7. France
  • 19.8. Russia
  • 19.9. Italy
  • 19.10. Spain
  • 19.11. China
  • 19.12. India
  • 19.13. Japan
  • 19.14. Australia
  • 19.15. South Korea

20. United States Viral Vector & Plasmid DNA Manufacturing Market

21. China Viral Vector & Plasmid DNA Manufacturing Market

22. Competitive Landscape

  • 22.1. Market Concentration Analysis, 2025
    • 22.1.1. Concentration Ratio (CR)
    • 22.1.2. Herfindahl Hirschman Index (HHI)
  • 22.2. Recent Developments & Impact Analysis, 2025
  • 22.3. Product Portfolio Analysis, 2025
  • 22.4. Benchmarking Analysis, 2025
  • 22.5. Advanced BioScience Laboratories, Inc.
  • 22.6. Akron Biotech
  • 22.7. Aldevron, LLC
  • 22.8. Avid Bioservices, Inc.
  • 22.9. Batavia Biosciences B.V.
  • 22.10. BioNTech IMFS GmbH
  • 22.11. BioSpace, Inc.
  • 22.12. Biovian Oy
  • 22.13. c-LEcta GmbH
  • 22.14. Catalent, Inc.
  • 22.15. Charles River Laboratories International, Inc.
  • 22.16. Creative Biogene
  • 22.17. Cytiva by Danaher Corporation
  • 22.18. FILTROX AG
  • 22.19. Forge Biologics By Ajinomoto Co., Inc.
  • 22.20. FUJIFILM Diosynth Biotechnologies Inc.
  • 22.21. GE HealthCare Technologies, Inc.
  • 22.22. Genentech, Inc.
  • 22.23. GeneOne Life Science, Inc.
  • 22.24. Genezen Laboratories, Inc.
  • 22.25. GenScript Biotech Corporation
  • 22.26. Hillgene Biopharma Co., Ltd.
  • 22.27. Kaneka Eurogentec S.A.
  • 22.28. Lonza Group Ltd.
  • 22.29. Merck KGaA
  • 22.30. Miltenyi Biotec B.V. & Co. KG
  • 22.31. Oxford Biomedica plc
  • 22.32. POLYPLUS TRANSFECTION S.A.
  • 22.33. REGENXBIO Inc.
  • 22.34. Revvity, Inc.
  • 22.35. Takara Bio Inc.
  • 22.36. Thermo Fisher Scientific Inc.
  • 22.37. Twist Bioscience Corporation
  • 22.38. uniQure N.V.
  • 22.39. Wuxi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 17. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PLASMID DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PLASMID DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ADENO-ASSOCIATED VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ADENO-ASSOCIATED VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ADENO-ASSOCIATED VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ADENOVIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ADENOVIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ADENOVIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY LENTIVIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY LENTIVIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY LENTIVIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RETROVIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RETROVIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RETROVIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ANALYTICAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ANALYTICAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ANALYTICAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SCALE-UP/TECHNOLOGY TRANSFER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SCALE-UP/TECHNOLOGY TRANSFER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SCALE-UP/TECHNOLOGY TRANSFER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGULATORY & CMC SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGULATORY & CMC SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGULATORY & CMC SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CAPTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CAPTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CAPTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CLARIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CLARIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CLARIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CONCENTRATION/BUFFER EXCHANGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CONCENTRATION/BUFFER EXCHANGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CONCENTRATION/BUFFER EXCHANGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INTERMEDIATE PURIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INTERMEDIATE PURIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INTERMEDIATE PURIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY POLISHING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY POLISHING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY POLISHING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY FILL & FINISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY FILL & FINISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY FILL & FINISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RELEASE & STABILITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RELEASE & STABILITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RELEASE & STABILITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOREACTOR PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOREACTOR PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOREACTOR PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL EXPANSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL EXPANSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL EXPANSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION/TRANSDUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION/TRANSDUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION/TRANSDUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INSECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INSECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INSECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY MAMMALIAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY MAMMALIAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY YEAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY YEAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY YEAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ADHERENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ADHERENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ADHERENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY FED-BATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY FED-BATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY FED-BATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PERFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PERFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PERFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY OUTSOURCED/CDMO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY OUTSOURCED/CDMO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY OUTSOURCED/CDMO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ONCOLYTIC VIROTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RESEARCH & DEVELOPEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RESEARCH & DEVELOPEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RESEARCH & DEVELOPEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VACCINE DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VACCINE DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY HEPATIC DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY HEPATIC DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY HEPATIC DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY METABOLIC/ENDOCRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY METABOLIC/ENDOCRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY METABOLIC/ENDOCRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY MUSCULOSKELETAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY MUSCULOSKELETAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY MUSCULOSKELETAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RARE GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RARE GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RARE GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 195. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 232. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2018-2032 (USD MILLION)
  • TABLE 234. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2018-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW ST